Clinical Trial Detail

NCT ID NCT03447769
Title Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: (None)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

lung non-small cell carcinoma

Therapies

Canakinumab

Age Groups: senior adult

No variant requirements are available.